Cardiovascular Risk Assessment in Women: Which Women Are Suited for Menopausal Hormone Therapy?
Source : https://pubmed.ncbi.nlm.nih.gov/37931647/
Individual risk assessment for atherosclerotic cardiovascular disease is important for safe menopausal hormone prescription.
Estimation of ASCVD risk in perimenopausal women needing MHT can be tailored by adding female-specific risk factors and a CAC score with computed tomography if there is doubt about individual risk.
Share
Prevalence and Impact of Vasomotor Symptoms due to Menopause Among Women in Brazil, Canada, Mexico, and Nordic Europe: a Cross-Sectional Survey
Researchers surveyed women aged 40 to 65 years in Brazil, Canada, Mexico, and 4 Nordic European countries (Denmark, Finland, Norway, and Sweden) using an online survey. Secondary objectives assessed impact...
A total of 37,206 women across Brazil, Canada, Mexico, and 4 Nordic European countries accessed the survey. Across regions, 44% never received any pharmacologic treatment, and 16.9% and 5.2% of respondents were taking prescription HT and non-HT medications, respectively, at the time of the survey.
Share
Fezolinetant blocks NKB binding on the kisspeptin/neurokinin B/dynorphin neuron, which modulates neuronal activity in the thermoregulatory center and decreases the number and intensity of hot flashes and night sweats.
Share
Relationships Between the Vaginal Microbiota and Genitourinary Syndrome of Menopause Symptoms in Postmenopausal Women: the Study of Women's Health Across the Nation
Source : https://pubmed.ncbi.nlm.nih.gov/37788422/
Although close relationships exist among estrogen, CSTs, VMI, and pH, sexual pain was the only GSM symptom associated with the structure of vaginal microbiota and atrophy biomarkers.
Although close relationships exist among estrogen, community state types, vaginal maturation index, and pH, sexual pain was the only symptom of the genitourinary syndrome of menopause associated with the structure of vaginal microbiota and atrophy biomarkers.
Share
This article describes the use of fezolinetant and neurokinin B antagonists as nonhormonal therapies for menopausal vasomotor symptoms.
Share